17D yellow fever vaccine elicits comparable long-term immune responses in healthy individuals and immune-compromised patients
- 24 March 2016
- journal article
- Published by Elsevier BV in Journal of Infection
- Vol. 72 (6), 713-722
- https://doi.org/10.1016/j.jinf.2016.02.017
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Comparison of the PRNT and an immune fluorescence assay in yellow fever vaccinees receiving immunosuppressive medicationVaccine, 2016
- Efficacy and Duration of Immunity after Yellow Fever Vaccination: Systematic Review on the Need for a Booster Every 10 YearsThe American Journal of Tropical Medicine and Hygiene, 2013
- Temporal Dynamics of the Primary Human T Cell Response to Yellow Fever Virus 17D As It Matures from an Effector- to a Memory-Type ResponseThe Journal of Immunology, 2013
- Immunogenicity and safety of yellow fever vaccine among 115 HIV-infected patients after a preventive immunisation campaign in MaliTransactions of the Royal Society of Tropical Medicine and Hygiene, 2012
- Plasma HIV-RNA Is the Key Determinant of Long-Term Antibody Persistence After Yellow Fever Immunization in a Cohort of 364 HIV-Infected PatientsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2012
- The Yellow Fever Virus Vaccine Induces a Broad and Polyfunctional Human Memory CD8+ T Cell ResponseThe Journal of Immunology, 2009
- Immunogenicity and Safety of Yellow Fever Vaccination for 102 HIV‐Infected PatientsClinical Infectious Diseases, 2009
- Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjectsVaccine, 2008
- Measles immunity testing: Comparison of two measles IgG ELISAs with plaque reduction neutralisation assayJournal of Virological Methods, 2005
- A haemorrhagic fever from the Côte d'lvoireThe Lancet, 1999